Skip to content

Released Nov 9, 2021, after the close

10-Q filed Nov 10, 2021, 41 days after period end · 0001564590-21-055843

Q3 2021 · 10-Q
Revenue$8.52M−52.2% vs Q3 2020−69.6% vs Q2 2021
Net Income-$30.90MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.67N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$34,674,000N/M
Operating Cash Flowderived-$24,406,000N/M
Margins · derived
Operating margin-407.1%−347.5 pt vs Q3 2020
Net margin-362.8%−459.0 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$8.52M$17.82M$12.28M$7.84M
Net Income-$30.90M$17.14M-$12.91M-$10.24M
EPS Diluted-$0.67$0.45-$0.56-$21.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR